Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

tudy

was initiated in June, 2007 and to date there has been in excess of

200 patients enrolled. The trial will include approximately 510

patients at approximately 65 sites across the U.S. The DSMB has

conducted its first review of the data from this trial and has

recommended it continue. The trial is expected to complete enrollment

in mid-2008.

- MINDSET-01: A phase II clinical trial evaluating MBP8298 for the

treatment of relapsing-remitting MS ("RRMS"). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in 6 countries across Europe. The DSMB has

completed three safety analyses to date and recommended that the

trial continue as per the protocol.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to its lead MS compound, MBP8298. Under the terms of the agreement, Lilly and BioMS will collaborate on the development of MBP8298 and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US$410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 is commercialized. BioMS will continue to oversee the current trials. The completion of the transaction resulted in licensing bonuses, as contemplated in a number of pre-existing employment agreements, paid to all Company personnel in February 2008 of $9.0 million which was reviewed and approved by the independent Compensation Committee, and supported by an independent compensation
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... San Bruno, CA (PRWEB) April 21, 2015 ... Expert CRO, will sponsor and exhibit at the ACRP ... in Salt Lake City, Utah. The Association of Clinical ... largest annual clinical research conference solely focused on the ... through membership, training and development, and widely recognized industry ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) announced today that it will release its ... Tuesday, April 28, 2015. United Therapeutics will ... at 9:00 a.m. Eastern Time.  The teleconference is accessible ... rebroadcast of the teleconference will be available for one ...
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... Cleveleys (UK) (PRWEB) April 21, 2015 ... technology and its clinical applications will be ... Participants include engineers, scientists, regulators and clinicians ... The meeting is sponsored by Invibio Biomaterial ... polymer-based biomaterials, a specialist in manufacturing and ...
Breaking Biology Technology:PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3
... Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... 16 /PRNewswire/ - Many companies in the cell therapy ... Hospira, Lonza and Life Technologies will join ISCT to ... greater strategic alignment within the industry and drive late ... Force (ITF), comprising these major corporations along with internationally ...
... ("CTI") (Nasdaq and MTA: CTIC) announced today that it ... has validated the expanded Pediatric Investigation Plan ("PIP") that ... of relapsed or refractory, aggressive non-Hodgkin,s lymphoma (NHL).  Following ... review and comment or approve the content of pediatric ...
Cached Biology Technology:Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 2Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 3Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 4Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 5Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 6Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 7Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 8Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 9Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 10Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 11Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 12Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 13Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 14International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership. 2EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP) 2EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP) 3
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... the amazing repertoire of carbon nanotubes -- the ability ... tiny hollow carbon filaments about one ten-thousandth the diameter ... of the most versatile materials ever discovered. A hundred ... able to conduct electricity better than copper or to ...
... just a few calories from the daily diet can do ... it may help lessen the effects of aging. , Scientists ... that eating a little less food and exercising a little ... cell and organ damage in rats. , The discovery, described ...
... University of New South Wales (UNSW) researchers have announced they ... the potential to treat a diverse range of health problems, ... The research is published in the July issue of Nature ... due to age-related macular degeneration (AMD) and diabetic retinopathy are ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Cutting calories slightly can reduce aging damage 2Cutting calories slightly can reduce aging damage 3'Molecular assassin' targets disease gene 2
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... dotLab System brings together two mature, ... immobilized capture surfaces. This combination produces ... for the detection of molecular binding ... labels. , Protein-specific capture molecules are ...
Biology Products: